PDCD1 and glioma: Very recently and for the first time in solid tumors, study on a recombinant anti-EGFRvIII CAR T-cell through co-disruption of TRAC, ß2 M and PDCD1 genes by means of CRISPR-Cas9 showed higher anti-glioma activities compared to previous anti-EGFRvIII CAR T-cell therapies [126].